Avalon Capital Management’s Proshares UltraPro NASDAQ Biotechnology UBIO Stock Holding History

Avalon Capital Management’s Portfolio UBIO Stock Details UBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-24,329	Closed	-$818K	–	90
2017 Q4	$818K	Buy	+24,329	New	+$831K	0.73%	46

Other funds holding UBIO

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

AIM

Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return

Avalon Capital Management's UBIO Position: Q1 2018 in Review

Avalon Capital Management sold out of Proshares UltraPro NASDAQ Biotechnology (UBIO) in Q1 2018, closing a stake of 24,329 shares — an estimated $818K sold.

Avalon Capital Management first reported a position in UBIO in Q4 2017 and held it in 1 quarter. The position peaked at $818K in Q4 2017. 6 funds tracked by Wall St. Rank hold UBIO as of Q1 2018.

Avalon Capital Management reported no remaining Proshares UltraPro NASDAQ Biotechnology position as of Q1 2018 after selling out during the quarter.
Avalon Capital Management sold 24,329 Proshares UltraPro NASDAQ Biotechnology shares in Q1 2018, an estimated $818K.
Avalon Capital Management first reported a position in Proshares UltraPro NASDAQ Biotechnology in Q4 2017 and held it in 1 quarter.
Avalon Capital Management's Proshares UltraPro NASDAQ Biotechnology position peaked at $818K in Q4 2017.
6 funds tracked by Wall St. Rank held Proshares UltraPro NASDAQ Biotechnology as of Q1 2018.

Based on Avalon Capital Management's 13F filing for Q1 2018, filed 16 Apr 2018.